Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Receivables (2019 - 2025)

BioNexus Gene Lab's Receivables history spans 7 years, with the latest figure at $1.3 million for Q4 2025.

  • Quarterly results put Receivables at $1.3 million for Q4 2025, down 18.26% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (down 18.26% YoY), and the annual figure for FY2025 was $1.3 million, down 18.26%.
  • Receivables for Q4 2025 was $1.3 million at BioNexus Gene Lab, down from $1.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $4.2 million in Q3 2021 to a low of $922106.0 in Q4 2023.
  • The 5-year median for Receivables is $2.1 million (2023), against an average of $2.3 million.
  • The sharpest move saw Receivables tumbled 68.13% in 2023, then skyrocketed 77.39% in 2025.
  • Year by year, Receivables stood at $3.4 million in 2021, then fell by 15.8% to $2.9 million in 2022, then tumbled by 68.13% to $922106.0 in 2023, then soared by 71.37% to $1.6 million in 2024, then decreased by 18.26% to $1.3 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $1.3 million, $1.6 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.